From the Editor on Menopausal hormone therapy for the primary prevention of chronic conditions - The U.S. Preventive Services Task Force draft recommendation statement

Abstract

On May 16, 2017, the U.S. Preventive Services Task Force requested comments on a draft recommendation statement and a draft evidence review on menopausal hormone therapy for the primary prevention of chronic conditions. Based on its review of the evidence, the Task Force recommends against the use of combined estrogen and progestin for the prevention of chronic conditions in postmenopausal women. Based on this document, we present a short review on estrogen physiology during menopause and subsequent recommendations by specialized institutions on estrogen and progestin hormone therapy for the prevention of chronic cardiovascular, vasomotor, neurological and osteoporotic symptoms.